Company profile AMAM
After 34 days of this quarter the interest is at 153.0. Based on that we can calculate that during remaining 58 days it will total up to 414.0. Ambrx Biopharma expected interest is significantly higher compared to previous quarter (+250.8%) and same quarter last year (+266.4%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 0 |
| 2019 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 54 inf% YoY inf% QoQ | 10 inf% YoY -81.5% QoQ |
| 2021 | 44 inf% YoY 340.0% QoQ | 113 inf% YoY 156.8% QoQ | 30 -44.4% YoY -73.5% QoQ | 55 450.0% YoY 83.3% QoQ |
| 2022 | 15 -65.9% YoY -72.7% QoQ | 34 -69.9% YoY 126.7% QoQ | 97 223.3% YoY 185.3% QoQ | 113 105.5% YoY 16.5% QoQ |
| 2023 | 83 453.3% YoY -26.5% QoQ | 54 58.8% YoY -34.9% QoQ | 118 21.6% YoY 118.5% QoQ | 153 35.4% YoY 29.7% QoQ |
The average 5 years interest of Ambrx Biopharma was 3.73 per week. The last year interest of Ambrx Biopharma compared to the last 5 years has changed by 168.63%. This is something to be checked. This didn't exist 5 years ago.
There is not enough data for ARX788 breast cancer to provide analysis
There is not enough data for ARX788 breast cancer to provide correlation calculation
There is not enough data for ARX788 breast cancer to provide analysis
There is not enough data for ARX788 gastric cancer to provide analysis
There is not enough data for ARX788 gastric cancer to provide correlation calculation
There is not enough data for ARX788 gastric cancer to provide analysis
There is not enough data for ARX788 clinical trials to provide analysis
There is not enough data for ARX788 clinical trials to provide correlation calculation
There is not enough data for ARX788 clinical trials to provide analysis
There is not enough data for ARX517 prostate cancer to provide analysis
There is not enough data for ARX517 prostate cancer to provide correlation calculation
There is not enough data for ARX517 prostate cancer to provide analysis
There is not enough data for ARX305 renal cell carcinoma to provide analysis
There is not enough data for ARX305 renal cell carcinoma to provide correlation calculation
There is not enough data for ARX305 renal cell carcinoma to provide analysis
There is not enough data for ARX102 IL-2 pathway agonist to provide analysis
There is not enough data for ARX102 IL-2 pathway agonist to provide correlation calculation
There is not enough data for ARX102 IL-2 pathway agonist to provide analysis
There is not enough data for Ambrx Biopharma collaborations to provide analysis
There is not enough data for Ambrx Biopharma collaborations to provide correlation calculation
There is not enough data for Ambrx Biopharma collaborations to provide analysis
There is not enough data for Ambrx Biopharma jobs to provide analysis
There is not enough data for Ambrx Biopharma jobs to provide correlation calculation
There is not enough data for Ambrx Biopharma jobs to provide analysis
After 39 days of this quarter the interest is at 173.0. Based on that we can calculate that during remaining 52 days it will total up to 404.0. Ambrx Biopharma -stock -company expected interest is significantly higher compared to previous quarter (+292.2%) and same quarter last year (+74.1%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 172 inf% QoQ | 117 -32.0% QoQ | 78 -33.3% QoQ |
| 2020 | 64 inf% YoY -17.9% QoQ | 92 -46.5% YoY 43.8% QoQ | 64 -45.3% YoY -30.4% QoQ | 21 -73.1% YoY -67.2% QoQ |
| 2021 | 170 165.6% YoY 709.5% QoQ | 148 60.9% YoY -12.9% QoQ | 33 -48.4% YoY -77.7% QoQ | 135 542.9% YoY 309.1% QoQ |
| 2022 | 107 -37.1% YoY -20.7% QoQ | 22 -85.1% YoY -79.4% QoQ | 213 545.5% YoY 868.2% QoQ | 183 35.6% YoY -14.1% QoQ |
| 2023 | 232 116.8% YoY 26.8% QoQ | 140 536.4% YoY -39.7% QoQ | 203 -4.7% YoY 45.0% QoQ | 103 -43.7% YoY -49.3% QoQ |
| 2024 | 173 -25.4% YoY 68.0% QoQ | - | - | - |
The average 5 years interest of Ambrx Biopharma -stock -company was 9.46 per week. The last year interest of Ambrx Biopharma -stock -company compared to the last 5 years has changed by 67.34%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 124.22%.